May 14th 2024
The phase 2 VERSATILE-002 trial evaluating Versamune HPV with pembrolizumab met its primary end point in patients with first-line recurrent metastatic head and neck squamous cell cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Smokers Develop Tobacco-Specific Mutations in HPV-Positive Oropharyngeal Squamous Cell Cancer
February 20th 2016Patients with HPV-positive oropharyngeal squamous cell cancer (OPSCC) who smoke can develop tobacco-associated mutations over time. These accumulated mutations result in less dependence on E6/E7 and other HPV-associated mutations.
Read More
Patient-Derived Xenografts Could Personalize Anaplastic Thyroid Cancer Care
February 17th 2016Anaplastic thyroid cancer is an extremely aggressive form of cancer that cannot be cured by surgery and has a median survival of about 6 months. The malignancy normally occurs in patients over the age of 60, and there is not a standard of care, according to John A. Copland III, PhD, professor, Cancer Biology, Mayo Clinic.
Read More
Dr. Sylvia Asa on Treating Different Types of Thyroid Cancer
February 16th 2016Asa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.
Watch
Nivolumab Could Change Head and Neck Cancer Treatment Paradigm
February 16th 2016With the phase III CheckMate-141 trial being stopped early due to the anti-PD-1 agent nivolumab having met its primary endpoint of overall survival improvement in head and neck cancer, Robert Ferris, MD, PhD, couldn't be more elated.
Read More
T-Cell Therapy Granted FDA Breakthrough Designation in Sarcoma
February 11th 2016The FDA has granted an affinity enhanced T-cell therapy breakthrough therapy designation for patients with inoperable or metastatic pretreated synovial sarcoma who harbor HLA-A*201, HLA-A*205, or HLA-A*206 alleles and whose tumors express the NY-ESO-1 tumor antigen
Read More
New Study Seeks to Assess Tolerability of Emerging Nivolumab Combination
December 29th 2015An upcoming phase I trial seeks to evaluate a combination of interferon gamma-1b (ACTIMMUNE) and nivolumab (Opdivo) in patients with advanced solid tumors who have progressed on at least one prior systemic therapy.
Read More
FDA Approves Non-Alcohol Formulation of Docetaxel for Multiple Cancer Types
December 29th 2015The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
Read More
Tumor Treating Fields Device Shows Survival Advantage
December 18th 2015Patients with newly-diagnosed glioblastoma who received treatment with tumor- treating electrical fields in addition to temozolomide had nearly double the two-year survival of those who received temozolomide alone, according to an article published in the Journal of the American Medical Association.
Read More
Dr. Barbara Burtness on the Psychology of Talking to Patients About Enrolling in Clinical Trials
December 8th 2015Burtness says on average, medical professionals should take about 4 minutes or longer to properly explain the clinical trial to their patients, as well as leave ample time for questions at the end of the conversation.
Watch
Pilot Study for EGFRvIII-positive Glioblastoma Treatment Shows Promise
November 23rd 2015A chimeric antigen receptor T-cell therapy used in patients with EGFRvIII-positive glioblastoma multiforme during a pilot study showed promising results, according to two leading researchers in the field presenting at the 2015 Society of Neuro-Oncology Annual Meeting.
Read More
Dendritic Vaccines Improves Survival in GBM Subset
November 22nd 2015Phase II findings have shown a substantial improvement in overall survival with the dendritic vaccine ICT-107 in a subgroup of patients with HLA-A2+ newly diagnosed glioblastoma multiforme (GBM), warranting further exploration in a phase III study.
Read More
Dr. Carl June Discusses Management of Neurotoxicity From CAR T-Cell Therapy
November 21st 2015Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.
Read More
Immune Checkpoint Inhibitors Show Promise in Glioblastoma Treatment
November 21st 2015An emerging class of immune checkpoint blockade drugs has produced impressive benefits for patients in many solid tumor types. The class' success hints that these drugs ay be successful against central nervous system tumors as well, including glioblastoma.
Read More
Dr. Rimas Lukas on the Future of Checkpoint Inhibitors in Recurrent Glioblastoma
November 20th 2015Rimas Lukas, MD, director, Medical Neuro-Oncology, co-director, Neurology Medical Student Clerkship Program, The University of Chicago Medical Center, on PD-L1 blockade treatment and its potential in patients with recurrent glioblastoma (GBM).
Watch